JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on May 11, 2007; DOI: 10.1124/jpet.107.122036


0022-3565/07/3222-721-729$20.00
JPET 322:721-729, 2007
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.107.122036v1
322/2/721    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Giustizieri, M.
Right arrow Articles by Berretta, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Giustizieri, M.
Right arrow Articles by Berretta, N.

NEUROPHARMACOLOGY

Memantine Inhibits ATP-Dependent K+ Conductances in Dopamine Neurons of the Rat Substantia Nigra Pars Compacta

Michela Giustizieri, Maria Letizia Cucchiaroni, Ezia Guatteo, Giorgio Bernardi, Nicola B. Mercuri, and Nicola Berretta

Fondazione Santa Lucia Istituto di Ricovero e Cura a Carattere Scientifico, Laboratory of Experimental Neurology (M.G., M.L.C., E.G., G.B., N.B.M., N.B.) and Department of Neuroscience, University of Rome "Tor Vergata" (G.B., N.B.M.), Rome, Italy

1-Amino-3,5-dimethyl-adamantane (memantine) is a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist used in clinical practice to treat neurodegenerative disorders that could be associated with excitotoxic cell death. Because memantine reduces the loss of dopamine neurons of the substantia nigra pars compacta (SNc) in animal models of Parkinson's disease, we examined the effects of this drug on dopamine cells of the SNc. Besides inhibition of NMDA receptor-mediated currents, memantine (30 and 100 µM) increased the spontaneous firing rate of whole-cell recorded dopamine neurons in a midbrain slice preparation. Occasionally, a bursting activity was observed. These effects were independent from the block of NMDA receptors and were prevented in neurons dialyzed with a high concentration of ATP (10 mM). An increase in firing rate was also induced by the ATP-sensitive potassium (KATP) channel antagonist tolbutamide (300 µM), and this increase occluded further effects of memantine. In addition, KATP channel-mediated outward currents, induced by hypoxia, were inhibited by memantine (30 and 100 µM) in the presence of the NMDA receptor antagonist (5S, 10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate (MK-801) (10 µM). An increase in the spontaneous firing rate by memantine was observed in dopamine neurons recorded with extracellular planar 8 x 8 multielectrodes in conditions of hypoglycemia. These results highlight KATP channels as possible relevant targets of memantine effects in the brain. Moreover, in view of a proposed role of KATP conductances in dopamine neuron degeneration, they suggest another mechanism of action underlying the protective role of memantine in Parkinson's disease.


Received March 5, 2007; accepted May 10, 2007.

Address correspondence to: Nicola Berretta, Fondazione Santa Lucia I.R.C.C.S., Via del Fosso di Fiorano, 64, 00143 Rome, Italy. E-mail: n.berretta{at}hsantalucia.it







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.